DUSP22 and metabolic dysfunction-associated steatohepatitis: Together, these findings demonstrated that DUSP22 directly interacted with FAK and inhibited FAK activation mainly at Y576 + Y577 and Y397, which was essential for the anti-NASH effects of DUSP22 both in vivo and in vitro.